Elevated tissue factor pathway inhibitor delays thrombin generation in COVID-19 but is not associated with clinical outcomes
Abstract: Plasma levels of tissue factor pathway inhibitor (TFPI) are elevated in many patients with COVID-19 but the role of TFPI in COVID-19 coagulopathy remains elusive. We sought to determine the contribution of TFPI to thrombin generation in patients with COVID-19 and assess its association wit...
Saved in:
Main Authors: | Alicia S. Eustes, Meena Kumari Palani Kumar, Julie A. Peterson, Alan E. Mast, Steven R. Lentz, Sanjana Dayal |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-08-01
|
Series: | Blood Vessels, Thrombosis & Hemostasis |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2950327225000282 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality
by: B. A. Tatarsky, et al.
Published: (2020-05-01) -
A Delayed Presentation of Immune Checkpoint Inhibitor Colitis
by: Alicia Nahhas, et al.
Published: (2025-06-01) -
CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor
Published: (2025-07-01) -
Expression of Procoagulant Microparticles Assessed by Thrombin Generation Test in Cirrhosis
by: Mejda Belakremi MD, et al.
Published: (2025-07-01) -
Research progress on clinical application of anti-tissue factor pathway inhibitor in hemophilia
by: XIAO Jianwen, YI Weijia
Published: (2025-04-01)